국전약품

307750KOSDAQ의약품 제조업

38.0 / 100

Reference Date: 2026-04-13

Financial Score6.5 / 40

News Sentiment17.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Plunged 22.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Kukjeon Pharm operates two main business segments: the pharmaceutical division, focusing on the synthesis and distribution of active pharmaceutical ingredients (APIs), and the materials division, developing high-performance specialty materials for advanced industries such as OLEDs, semiconductors, and AI. The company is strengthening its competitiveness through new drug development and global market expansion.

Number of Employees

172people

Average Salary

68.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

2.11Industry Average 1.040.0Point

2.0x industry avg (risky)

ROE

-4.99Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

18.00Industry Average 11.980.5Point

1.5x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼446.9% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 70

Positive
샤페론, 경구용 알츠하이머 치료제 ‘누세린’ 임상 1상 성공
국전약품은 샤페론과 공동 개발 중인 경구용 알츠하이머병 치료제 '누세린'의 임상 1상을 성공적으로 완료하고, 글로벌 시장 진입을 위한 후속 임상에 나설 예정입니다.
Neutral
[서울데이터랩]‘휴림에이텍’ 30.00% 상한가 금일 증시 상승률 1위...
휴림에이텍과 인베니아의 주가 상승률에 대한 뉴스로, 국전약품과 직접적인 관련은 없습니다.

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 3,755Won52-week high 5,54052-week low 3,040

1-month return0.0Point

1m -22.26% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-03
Neutral정기주주총회결과2026-03-31
Neutral상호변경안내2026-03-31
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral투자판단관련주요경영사항(임상시험결과) (HY209 경구 알츠하이머 치매 치료제 제1상 임상시험의 결과보고서(CSR) 수령)2026-03-25